Celltaxis, LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
4
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 16, 2027The maintenance fee for Methods of Inhibiting Leukotriene A4 Hydrolase (US 10,350,197) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
- 1 fee due Feb 20, 2027The maintenance fee for Monamine and Monoamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase (US 10,385,007) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
- 1 fee due Jun 10, 2027The maintenance fee for Inhibitors of Leukotriene A4 Hydrolase (US 10,501,455) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
- 1 fee due Aug 6, 2027The maintenance fee for Method of Reducing Pulmonary Exacerbations in Respiratory Disease Patients (US 11,890,282) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,267,819 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase In force · Medium confidence | In force | Medium confidence | |
| US 12,173,009 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase In force · Medium confidence | In force | Medium confidence | |
| US 7,737,145 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase In force · High confidence | In force | High confidence | |
| US 8,569,303 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase In force · High confidence | In force | High confidence | |
| US 9,820,974 | Methods of Inhibiting Leukotriene A4 Hydrolase In force · Medium confidence | In force | Medium confidence | |
| US 10,350,197 | Methods of Inhibiting Leukotriene A4 Hydrolase In force · Medium confidence | In force | Medium confidence | |
| US 10,898,471 | Methods of Inhibiting Leukotriene A4 Hydrolase In force · Medium confidence | In force | Medium confidence | |
| US 10,501,455 | Inhibitors of Leukotriene A4 Hydrolase In force · Low confidence | In force | Low confidence | |
| US 10,202,334 | Pendant Amines and Derivatives as Inhibitors of Leukotriene A4 Hydrolase In force · High confidence | In force | High confidence | |
| US 10,202,362 | Inhibitors of Leukotriene A4 Hydrolase In force · High confidence | In force | High confidence |
Also on record, not counted in the 14: 7 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 no status recorded